ÃÀ¸ß÷
ÓªÒµ×Éѯ
Öйú£º
Email: marketing@medicilon.com.cn
ÓªÒµ×ÉѯרÏߣº400-780-8018
£¨½öÏÞЧÀÍ×Éѯ£¬£¬£¬£¬£¬ÆäËûÊÂÒËÇ벦´ò´¨É³×ܲ¿µç»°£©
´¨É³×ܲ¿µç»°: +86 (21) 5859-1500
ÍâÑó£º
+1(781)535-1428(U.S.)
0044 7790 816 954 (Europe)
Email:marketing@medicilon.com




1. 6ÔÂ3ÈÕ£¬£¬£¬£¬£¬Ê¯ËÄÒ©¼¯ÍÅ(02005.HK)Ðû²¼Í¨¸æ£¬£¬£¬£¬£¬¼¯ÍÅÒÑÈ¡µÃÖйú¹ú¼ÒÒ©Æ·¼àÊÓ¹ÜÀí¾ÖÓйرÈË÷Âå¶û°±ÂÈµØÆ½Æ¬(5mg)µÄÒ©Æ·Éú²ú×¢²áÅú¼þ£¬£¬£¬£¬£¬ÊôÓÚ»¯Ñ§Ò©Æ·µÚ4À࣬£¬£¬£¬£¬ÊÓͬͨ¹ýÒ»ÖÂÐÔÆÀ¼Û£¬£¬£¬£¬£¬ÊǺ£ÄÚÆóÒµµÚ¶þ¼Ò»ñÅú¡£¡£¡£¡£¡£±ÈË÷Âå¶û°±ÂÈµØÆ½Æ¬ÊǸ´·½ÖƼÁ£¬£¬£¬£¬£¬Ö÷ÒªÓÃÓÚ×÷Ϊ¸ßѪѹÖÎÁƵÄÌæ»»ÁÆ·¨¡£¡£¡£¡£¡£
2. 6ÔÂ3ÈÕ£¬£¬£¬£¬£¬ÒËÃ÷°º¿Æ-B(01541)Ðû²¼Í¨¸æ£¬£¬£¬£¬£¬¼¯ÍÅ»ñÖйú¹ú¼ÒÒ©Æ·¼àÊÓ¹ÜÀí¾Ö(¹ú¼ÒÒ©¼à¾Ö)Ò©Æ·ÉóÆÀÖÐÐÄ(Ò©Æ·ÉóÆÀÖÐÐÄ)Åú×¼¾ÙÐÐIMM01 (Ìæ´ïÅÉÎ÷ÆÕ)ÁªºÏ°¢Ôú°ûÜÕIIIÆÚÁÙ´²ÊÔÑ鼯»®£¬£¬£¬£¬£¬ÓÃÓÚÂýÐÔÁ£-µ¥ºËϸ°û°×Ѫ²¡ (CMML)µÄÒ»ÏßÖÎÁÆ¡£¡£¡£¡£¡£
3. 5ÔÂ31ÈÕ£¬£¬£¬£¬£¬Èüŵ·ÆÐû²¼ÆäÓ¤Ó×¶ù±ÇÅçºôÎüµÀºÏ°û²¡¶¾¼õ¶¾»îÒßÃç»ñ¹ú¼ÒÒ©¼à¾ÖÒ©Æ·ÉóÆÀÖÐÐÄÅú×¼£¬£¬£¬£¬£¬¿É¿ªÕ¹ÁÙ´²Ñо¿¡£¡£¡£¡£¡£ËüÊÇÈ«ÇòÊ׸öÉè¼ÆÓÃÓÚÔ¤·ÀºôÎüµÀºÏ°û²¡¶¾ÒýÆð¼²²¡µÄÓ¤Ó×¶ùÒßÃ磬£¬£¬£¬£¬¿ÉΪ 6 ÖÁ 24 ÔÂÁäµÄÓ¤Ó×¶ùÌṩ±£»£»£»£»¤¡£¡£¡£¡£¡£
4. ¿ËÈÕ£¬£¬£¬£¬£¬ÅɽðÉúÎï1ÀàÁ¢ÒìÒ©×¢ÉäÓÃÖØ×éõ£»£»£»£»¯ÒȸßѪÌÇËØÑùëÄ2ÀàËÆÎï»ñÅúÁÙ´²£¬£¬£¬£¬£¬Ë³Ó¦Ö¢Îª»¯ÁÆÏà¹ØÐÔ¸¹Ðº£¨Chemotherapy induced diarrhea, CID£©£¬£¬£¬£¬£¬PJ020ÊôÓÚ³¤Ð§ÒȸßѪÌÇËØÑùëÄ-2£¨GLP-2£©¡£¡£¡£¡£¡£
1. ¿ËÈÕ£¬£¬£¬£¬£¬Æ½°²¿µ½¡Ó볤´º½ðÈüÒ©ÒµÓÐÏÞÔðÈι«Ë¾ÔÚÉϺ£¾ÙÐÐÁËÕ½ÂÔÏàÖúǩԼÒÇʽ¡£¡£¡£¡£¡£´Ë´ÎÏàÖú±ê¼Ç×ÅË«·½½«ÅäºÏΪ¶ùͯÉú³¤·¢ÓýÈ«ÖÜÆÚ¹ÜÀíЧÀÍ×¢ÈëеĻîÁ¦¡£¡£¡£¡£¡£
1. 5ÔÂ29ÈÕ£¬£¬£¬£¬£¬ÖÐɽ´óѧÁ¥ÊôµÚÒ»Ò½ÔºÖÜâù¸±Ñо¿Ô±¡¢ÖÐɽһԺÄÚ¿ÆÖ÷ÈΡ¢ÉöÄÚ¿ÆÖ÷ÈΡ¢¹ú¼ÒÎÀ½¡Î¯ÉöÔà²¡ÖØµãʵÑéÊÒÖ÷ÈγÂá˽ÌÊÚ£¬£¬£¬£¬£¬ÃÀ¹ú¹þ·ð´óѧҽѧԺ Joseph V. Bonventre ½ÌÊÚµÈÍŶÓǿǿÁªºÏÔÚ Immunity ÔÓÖ¾½ÒÏþÑо¿£¬£¬£¬£¬£¬Ê״η¢Ã÷ÔÚÉöÏËά»¯Àú³ÌÖУ¬£¬£¬£¬£¬³¦µÀ ILC3 Äܹ»Í¨¹ý CXCR6/CXCL16 ÖáǨáãµ½ÉöÔà¡£¡£¡£¡£¡£Ç¨áãµ½ÉöÔàÄÚ ILC3 ±í´ï PD-1£¬£¬£¬£¬£¬µ÷Àí IL-23 ÊÜÌåµÄÄÚÍÌ×÷Ó㬣¬£¬£¬£¬ÔöÇ¿ IL-17A µÄ±¬·¢£¬£¬£¬£¬£¬´Ó¶ø¼Ó¾çÉöÔàÏËά»¯£¬£¬£¬£¬£¬¸Ãͨ·¶Ô ILC3 µÄ´ÙÏËά»¯×÷ÓÃÖÁ¹ØÖ÷Òª£¡
[1]Liang et al., Intestinal CXCR6+ ILC3s migrate to the kidney and exacerbate renal fibrosis via IL-23 receptor signaling enhanced by PD-1 expression, Immunity (2024).
Ïà¹ØÐÂÎÅ